Pure Global

A Multiple Dose Study Of PD-0360324 In Patients With Active Cutaneous Lupus Erythematosus - Trial NCT01470313

Access comprehensive clinical trial information for NCT01470313 through Pure Global AI's free database. This Phase 1 trial is sponsored by Pfizer and is currently Terminated. The study focuses on Cutaneous Lupus Erythematosus. Target enrollment is 28 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT01470313
Phase 1
Terminated
drug
Trial Details
ClinicalTrials.gov • NCT01470313
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
A Multiple Dose Study Of PD-0360324 In Patients With Active Cutaneous Lupus Erythematosus
A Randomized, Subject And Investigator-Blinded (Sponsor-Open), Placebo-Controlled Study To Evaluate The Safety, Tolerability, And Preliminary Efficacy Of Multiple Ascending Doses Of PD- 0360324 In Subjects With Active Cutaneous Lupus Erythematosus (CLE)

Study Focus

PD-0360324

Interventional

drug

Sponsor & Location

Pfizer

Anniston,Oxford,Los Angeles,Orange Park,Chicago,Indianapolis,Fort Gratiot,Charlotte,Ducansville,Philadelphia,Wyomissing,Rapid City,Rapid City,Jackson,Dallas,Norfolk,Clarksburg,Markham,Chisinau, Canada,Moldova - Republic of,United States of America

Timeline & Enrollment

Phase 1

Nov 01, 2011

Nov 01, 2013

28 participants

Primary Outcome

Safety and tolerability of PD- 0360324 will be assessed by physical examinations, adverse event and infection monitoring, 12 lead ECGs, vital sign, and clinical safety laboratory measurements.

Summary

This study is designed to evaluate the safety and tolerability of multiple intravenously
 administered doses of PD-0360324 in patients with cutaneous lupus erythematosus. Changes in
 disease activity will also be evaluated.

ICD-10 Classifications

Subacute cutaneous lupus erythematosus
Lupus erythematosus
Discoid lupus erythematosus
Systemic lupus erythematosus
Systemic lupus erythematosus, unspecified

Data Source

ClinicalTrials.gov

NCT01470313

Non-Device Trial